Valuation: ANI Pharmaceuticals, Inc.

Market Cap 1.51B 1.35B 1.25B 1.13B 2.14B 142B 2.2B 14.94B 5.95B 75.82B 5.66B 5.54B 240B P/E 2026 *
13.2x
P/E 2027 * 11.6x
Enterprise Value 1.66B 1.49B 1.37B 1.25B 2.36B 156B 2.42B 16.42B 6.54B 83.34B 6.23B 6.09B 263B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.18x
Free-Float
87.26%
Yield 2026 *
-
Yield 2027 * -
1 day+5.10%
1 week-1.43%
Current month-1.04%
1 month-3.57%
3 months-5.95%
6 months-12.96%
Current year-9.74%
1 week 67.14
Extreme 67.135
76
1 month 67.14
Extreme 67.135
76
Current year 67.14
Extreme 67.135
87.76
1 year 67.14
Extreme 67.135
89.57
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 08/09/2020
Director of Finance/CFO 55 06/05/2016
Compliance Officer - 24/02/2022
Director TitleAgeSince
Chairman 62 24/11/2025
Director/Board Member 68 06/08/2020
Director/Board Member 66 06/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
29/10/26 Sell

Chief Financial Officer

-2,850 0.0124%
15/10/26 Sell

Chief Executive Officer

-5,400 0.0235%
13/10/26 Sell

General Counsel

-500 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+5.10%-1.43%-19.88%+36.60% 1.51B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
+0.17%+2.76%+44.07%+69.71% 388B
-0.48%+2.34%+70.66%+46.02% 365B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average +0.48%+1.70%+35.21%+79.18% 428B
Weighted average by Cap. -0.09%+2.51%+43.69%+97.12%

Financials

2026 *2027 *
Net sales 1.1B 985M 907M 824M 1.56B 103B 1.6B 10.87B 4.33B 55.15B 4.12B 4.03B 174B 1.22B 1.09B 1.01B 914M 1.73B 114B 1.78B 12.06B 4.8B 61.2B 4.57B 4.48B 193B
Net income 121M 108M 99.61M 90.46M 171M 11.3B 176M 1.19B 475M 6.05B 452M 443M 19.14B 136M 122M 113M 102M 194M 12.8B 199M 1.35B 538M 6.86B 512M 501M 21.67B
Net Debt 150M 134M 124M 112M 213M 14.04B 219M 1.48B 590M 7.52B 562M 550M 23.77B -69.14M -62.01M -57.14M -51.9M -98.22M -6.48B -101M -684M -273M -3.47B -259M -254M -10.98B
Projected Income Statement - Annual - ANI Pharmaceuticals, Inc.
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
10/11/26 US$71.25 +5.10% 1,188,614
09/11/26 US$67.79 +0.56% 483,964
06/11/26 US$67.41 -3.17% 578,180
05/11/26 US$69.62 -2.83% 1,295,663
04/11/26 US$71.65 -0.87% 304,431
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - ANI Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
71.25USD
Average target price
105.22USD
Spread / Average Target
+47.68%
  1. Stock Market
  2. Stocks
  3. ANIP Stock